Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference
September 21, 2023 07:30 ET
|
Sensei Biotherapeutics
- New data from multi-dose GLP toxicology study of SNS-101 in cynomolgus monkeys further support exceptional PK and safety profile - - Mechanistic mouse data show SNS-101 drives tumor macrophages to...
Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference
September 13, 2023 07:30 ET
|
Sensei Biotherapeutics
BOSTON, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation...
Sensei Biotherapeutics to Participate in Upcoming Investor Conferences
August 30, 2023 07:30 ET
|
Sensei Biotherapeutics
BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation...
Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
August 03, 2023 07:30 ET
|
Sensei Biotherapeutics
Phase 1/2 clinical trial enrolling for lead investigational candidate SNS-101, a conditionally active VISTA-blocking antibody for the treatment of advanced solid tumors A total of 6 patients in...
Sensei Biotherapeutics to Participate in Canaccord Genuity’s 43rd Annual Growth Conference
August 02, 2023 07:30 ET
|
Sensei Biotherapeutics
BOSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation...
Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101’s Potential as a Transformative Treatment Option for Patients with Solid Tumors”
June 13, 2023 07:30 ET
|
Sensei Biotherapeutics
- Featuring Dr. James Gulley, Co-Director of the Center for Immuno-Oncology at the National Cancer Institute (NCI) and internationally recognized expert on cancer immunotherapy - - Pre-registration...
Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors
June 01, 2023 07:30 ET
|
Sensei Biotherapeutics
- Topline Phase 1 monotherapy and initial combination data expected in 2024 - BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage immuno-oncology...
Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference
May 31, 2023 07:30 ET
|
Sensei Biotherapeutics
BOSTON, May 31, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation...
Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 09, 2023 07:30 ET
|
Sensei Biotherapeutics
- Investigational New Drug (IND) application for SNS-101 cleared by U.S. Food and Drug Administration (FDA) with first patient dose in Phase 1/2 trial expected in mid-2023 - - Signing of key...
Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody
April 20, 2023 07:30 ET
|
Sensei Biotherapeutics
BOSTON, April 20, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer...